RPRX Key Statistics, Chart & Performance
The current stock price of RPRX is 38.09 USD. In the past month the price decreased by -1.17%. In the past year, price increased by 53.34%.
RPRX Latest News, Press Relases and Analysis
RPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.67 | 928.57B | ||
| JNJ | JOHNSON & JOHNSON | 19.26 | 481.76B | ||
| MRK | MERCK & CO. INC. | 11 | 240.48B | ||
| PFE | PFIZER INC | 7.92 | 144.02B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.72 | 103.11B | ||
| ZTS | ZOETIS INC | 18.26 | 51.01B | ||
| VTRS | VIATRIS INC | 4.8 | 12.89B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.28 | 10.15B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.49 | 8.75B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.32B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.20B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.55B |
Related stock screener links
About RPRX
Company Profile
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.
Company Info
ROYALTY PHARMA PLC- CL A
110 East 59th Street
New York City NEW YORK 10022 US
CEO: Pablo Legorreta
Employees: 99
Phone: 12128830200
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you describe the business of ROYALTY PHARMA PLC- CL A?
Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.
What is the stock price of ROYALTY PHARMA PLC- CL A today?
The current stock price of RPRX is 38.09 USD. The price decreased by -1.5% in the last trading session.
What is the dividend status of ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a dividend yield of 2.25%. The yearly dividend amount is currently 0.63.
How is the ChartMill rating for ROYALTY PHARMA PLC- CL A?
RPRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
When does ROYALTY PHARMA PLC- CL A (RPRX) report earnings?
ROYALTY PHARMA PLC- CL A (RPRX) will report earnings on 2026-02-09, after the market close.
Can you provide the ownership details for RPRX stock?
You can find the ownership structure of ROYALTY PHARMA PLC- CL A (RPRX) on the Ownership tab.
What is the outstanding short interest for ROYALTY PHARMA PLC- CL A?
The outstanding short interest for ROYALTY PHARMA PLC- CL A (RPRX) is 6.19% of its float.
RPRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RPRX. When comparing the yearly performance of all stocks, RPRX is one of the better performing stocks in the market, outperforming 88.61% of all stocks.
RPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RPRX. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health.
RPRX Financial Highlights
Over the last trailing twelve months RPRX reported a non-GAAP Earnings per Share(EPS) of 4.11. The EPS increased by 0.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.55% | ||
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| Debt/Equity | 1.34 |
RPRX Forecast & Estimates
15 analysts have analysed RPRX and the average price target is 46 USD. This implies a price increase of 20.77% is expected in the next year compared to the current price of 38.09.
For the next year, analysts expect an EPS growth of 17.35% and a revenue growth 15.78% for RPRX